Valuation: Impax Laboratories Inc

Market Cap 5.66B 4.98B 4.63B 4.26B 7.98B 548B 8.12B 55.33B 21.58B 267B 21.26B 20.8B 928B P/E 2026 *
48.3x
P/E 2027 * 22.5x
Enterprise Value 7.92B 6.96B 6.47B 5.95B 11.16B 767B 11.36B 77.37B 30.18B 374B 29.73B 29.08B 1,298B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.25x
Free-Float
47.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2019
Chief Executive Officer 54 01/08/2019
Director of Finance/CFO 58 07/11/2023
Director TitleAgeSince
Director/Board Member 59 07/11/2023
Director/Board Member 70 07/11/2023
Director/Board Member 52 07/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 5.66B
+1.61%+1.45%+48.48%+158.24% 1,037B
+0.98%+3.48%+52.97%+51.20% 615B
+1.41%+1.16%+35.05%+79.72% 448B
+5.14%+5.40%+33.75%+27.79% 326B
+1.85%+3.57%+37.09%+40.59% 293B
-0.11%+0.48%+18.87%+17.70% 264B
+0.25%-4.62%-27.66%-41.76% 216B
+0.26%-1.04%+18.92%+56.20% 198B
-0.38%-4.59%+14.52%+67.46% 162B
Average +0.88%+1.12%+25.78%+50.79% 395.27B
Weighted average by Cap. +1.42%+1.47%+35.28%+75.88%

Financials

2026 *2027 *
Net sales 3.12B 2.74B 2.55B 2.34B 4.39B 302B 4.47B 30.44B 11.87B 147B 11.7B 11.44B 511B 3.33B 2.93B 2.72B 2.5B 4.69B 322B 4.78B 32.52B 12.69B 157B 12.5B 12.23B 545B
Net income 122M 107M 99.63M 91.63M 172M 11.81B 175M 1.19B 465M 5.76B 458M 448M 19.98B 263M 231M 215M 198M 371M 25.48B 377M 2.57B 1B 12.43B 988M 967M 43.12B
Net Debt 2.26B 1.98B 1.84B 1.7B 3.18B 218B 3.24B 22.04B 8.6B 107B 8.47B 8.29B 370B 1.81B 1.59B 1.48B 1.36B 2.56B 176B 2.6B 17.72B 6.91B 85.66B 6.81B 6.66B 297B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-